FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.

MLA

Pyrzynska, Beata, et al. “FOXO1 Promotes Resistance of Non-Hodgkin Lymphomas to Anti-CD20-Based Therapy.” Oncoimmunology, vol. 7, no. 5, Jan. 2018, p. e1423183. EBSCOhost, https://doi.org/10.1080/2162402X.2017.1423183.

APA

Pyrzynska, B., Dwojak, M., Zerrouqi, A., Morlino, G., Zapala, P., Miazek, N., Zagozdzon, A., Bojarczuk, K., Bobrowicz, M., Siernicka, M., Machnicki, M. M., Gobessi, S., Barankiewicz, J., Lech-Maranda, E., Efremov, D. G., Juszczynski, P., Calado, D., Golab, J., & Winiarska, M. (2018). FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology, 7(5), e1423183. https://doi.org/10.1080/2162402X.2017.1423183

Chicago

Pyrzynska, Beata, Michal Dwojak, Abdessamad Zerrouqi, Giulia Morlino, Piotr Zapala, Nina Miazek, Agnieszka Zagozdzon, et al. 2018. “FOXO1 Promotes Resistance of Non-Hodgkin Lymphomas to Anti-CD20-Based Therapy.” Oncoimmunology 7 (5): e1423183. doi:10.1080/2162402X.2017.1423183.